Equatorial GuineaTuberculosis profile
Population  2015 <1 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.063 (0.04–0.092) 7.5 (4.8–11)
Mortality (HIV+TB only) 0.12 (0.032–0.27) 14 (3.8–32)
Incidence  (includes HIV+TB) 1.5 (1.3–1.6) 172 (150–194)
Incidence (HIV+TB only) 0.73 (0.62–0.84) 86 (74–99)
Incidence (MDR/RR-TB)** 0.066 (<0.01–0.12) 7.8 (1–14)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.099 (0.073–0.13) 0.56 (0.43–0.69) 0.66 (0.5–0.82)
Males 0.066 (0.047–0.085) 0.72 (0.57–0.88) 0.79 (0.62–0.96)
Total 0.17 (0.13–0.2) 1.3 (1.2–1.4) 1.5 (1.3–1.6)
TB case notifications, 2015  
Total cases notified 1 286
Total new and relapse 1 242
          - % tested with rapid diagnostics at time of diagnosis 17%
          - % with known HIV status 73%
          - % pulmonary 91%
          - % bacteriologically confirmed among pulmonary 72%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 86% (76–98)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.13 (0.06–0.23)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 452 50%
          - on antiretroviral therapy 294 65%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  55
(8–100)
Estimated % of TB cases with MDR/RR-TB 2.8% (0.1–6.7) 21% (2.2–39)  
% notified tested for rifampicin resistance 11% 32% 164
MDR/RR-TB cases tested for resistance to second-line drugs   18
Laboratory-confirmed cases MDR/RR-TB: 39, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 26, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 58% 551
Previously treated cases, excluding relapse, registered in 2014 14% 78
HIV-positive TB cases, all types, registered in 2014 28% 287
MDR/RR-TB cases started on second-line treatment in 2013    
XDR-TB cases started on second-line treatment in 2013    
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 2%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data